Health Condition 1: null- neurologically stable patients
Conditions
Interventions
Intervention1: Patients with glial neoplasm: DEXMEDETOMIDINE will be given as infusion 1 microgram/kg over 10 minutes. (single dosage)
Intervention2: inj.dexmedetomidine: cerebral autoregulation will
Sponsors
Sri Chitra Tirunal Institute for Medical Science and Technology
Eligibility
Inclusion criteria
Inclusion criteria: two groups (15 patients in each group) Group I - patients with unilateral Glioma, Glascow coma scale 15, American society of anesthesiology Grading 1 and 2. Group II - patients having no intracranial pathology ( patients posted for lumbar and thoracic spinal cord surgeries (laminectomy, discectomy), American society of anesthesiology Grading 1 and 2.
Exclusion criteria
Exclusion criteria: Patient refusal, American society of Anesthesiology (ASA) class 3 and above, Age less than 18 years and more than 35 years, Preoperative Glasgow coma scale (GCS) Antihypertensive medication with alpha-methyldopa, clonidine or other a2-adrenergic agonist, Vascular pathology ( Plaque, calcification, narrowing, stenosis, abnormal flow pattern ) identified during pre-induction sonography, Difficulty in localizing intracranial vasculature by TCCDI, Abnormal bone window, Participation in another drug study during the preceding 1 month period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| effect of dexmedetomidine on cerebral vascular autoregulationTimepoint: immediately after completion of Dexmedetomidine infusion | — |
Secondary
| Measure | Time frame |
|---|---|
| cerebral hemodynamics, and cerebral vascular resistanceTimepoint: immediately after infusion of Dexmedetomidine | — |
Countries
India
Contacts
Public ContactARULVELAN
Sree Chitra tirunal institute for medical sccience and technology
Outcome results
None listed